Top

Published in:

01-04-2019 | Original Article

Desumoylating Isopeptidase 2 (DESI2) Inhibits Proliferation and Promotes Apoptosis of Pancreatic Cancer Cells through Regulating PI3K/AKT/mTOR Signaling Pathway

Authors: Xi Ou, Guang-tao Zhang, Zhe Xu, Jing-sen Chen, Yong Xie, Ji-Kui Liu, Xiao-Ping Liu

Published in: Pathology & Oncology Research | Issue 2/2019

Abstract

This study aimed to investigate the effects of desumoylating isopeptidase 2 (DESI2) on tumor cell proliferation, apoptosis and invasion of pancreatic cancer, and to assess the signaling pathway involved. Overexpression and silence of DESI2 were designed and the experiments were divided into 5 groups: a normal control group, an interference control group (shRNA-NC); an interference group (sh-DESI2); an overexpression control group (NC), an overexpression group (DESI2). Quantitative real time polymerase chain reaction (qRT-PCR) was used to screen the appropriate interference sequence. The silencing and overexpression of DESI2 were confirmed by qRT-PCR and western blotting. Cell cycling, apoptosis, invasion, and the expression of phosphatidylinositol-3-kinase (PI3K)-protein kinase B (AKT)-mammalian target of rapamycin (mTOR) pathway and caspase 3 were measured. Overexpression and silence of DESI2 were successfully designed in two pancreatic cancer cells, and the interference effect of sh-DESI2–3 showed the best silencing effects. The biological activities of DESI2 were detected in both ASPC-1 and PANCE-1 cells. Our results showed that cell proliferation was significantly increased in the sh-DESI2 group, while decreased in DESI2 group compared with the control group in both cell lines. In ASPC-1 cells, the events in G1 phase decreased and in S phase increased obviously in the sh-DESI2 group, compared with control group. An opposite result was found when DESI2 was overexpressed. In PANCE-1 cells, the events in G2 phase were higher in the sh-DESI2 group, while in the DESI2 group was significantly lower than that in control group. In ASPC-1 and PANCE-1 cells, sh-DESI2 group showed decreased apoptosis, increased cell invasion and increased expression of AKT, p-Akt, PI3K, p-PI3K, p-mTOR and mTOR and decreased caspase 3 expression compared with the control group, while overexpression of DESI2 leaded to increased apoptosis, decreased cell invasion and reduced expression of AKT, p-Akt, PI3K, p-PI3K, p-mTOR and mTOR and increased expression of caspase 3. DESI2 regulates the proliferation and apoptosis of pancreatic cancer cells through PI3K/AKT/mTOR signaling pathway.

Seipel AH, Wiklund F, Wiklund NP, Egevad L (2013) Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens. Virchows Arch 462(4):429–436. https://doi.org/10.1007/s00428-013-1385-5 CrossRefPubMed

Lin C, Yan H, Yang J, Li L, Tang M, Zhao X, Nie C, Luo N, Wei Y, Yuan Z (2017) Combination of DESI2 and IP10 gene therapy significantly improves therapeutic efficacy against murine carcinoma. Oncotarget 8(34):56281–56295. https://doi.org/10.18632/oncotarget.17623 CrossRefPubMedPubMedCentral

Shen CC, Cui XY, He Y, Kang YH, Yi C, Yang JL, Gou LT (2015) High phosphorylation status of AKT/mTOR signal in DESI2-reduced pancreatic ductal adenocarcinoma. Pathol Oncol Res 21(2):267–272. https://doi.org/10.1007/s12253-014-9817-3 CrossRefPubMed

Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703. https://doi.org/10.1056/NEJMoa1304369 CrossRef

Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R (2012) PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol Off J Am Soc Clin Oncol 30(8):777–782. https://doi.org/10.1200/JCO.2011.36.1196 CrossRef

Zhu G, Liu Y, Wang Y, Bi X, Baudry M (2015) Different patterns of electrical activity lead to long-term potentiation by activating different intracellular pathways. J Neurosci 35(2):621–633. https://doi.org/10.1523/JNEUROSCI.2193-14.2015 CrossRefPubMedPubMedCentral

Li J, Yang S, Zhu G (2017) Postnatal calpain inhibition elicits cerebellar cell death and motor dysfunction. Oncotarget 8(50):87997–88007. https://doi.org/10.18632/oncotarget.21324 CrossRefPubMedPubMedCentral

Lastwika KJ, Wilson W 3rd, Li QK, Norris J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM, Yao S, Liu LN, Gills JJ, Dennis PA (2016) Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung Cancer. Cancer Res 76(2):227–238. https://doi.org/10.1158/0008-5472.CAN-14-3362 CrossRefPubMed

Li J, Liang X, Yang X (2012) Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-kappaB pathways. Oncol Rep 28(2):501–510. https://doi.org/10.3892/or.2012.1827 CrossRefPubMed

10.

Zhu G, Wang X, Wu S, Li Q (2012) Involvement of activation of PI3K/Akt pathway in the protective effects of puerarin against MPP+−induced human neuroblastoma SH-SY5Y cell death. Neurochem Int 60(4):400–408. https://doi.org/10.1016/j.neuint.2012.01.003 CrossRefPubMed

11.

Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, Wagner L, Shenmen CM, Schuler GD, Altschul SF, Zeeberg B, Buetow KH, Schaefer CF, Bhat NK, Hopkins RF, Jordan H, Moore T, Max SI, Wang J, Hsieh F, Diatchenko L, Marusina K, Farmer AA, Rubin GM, Hong L, Stapleton M, Soares MB, Bonaldo MF, Casavant TL, Scheetz TE, Brownstein MJ, Usdin TB, Toshiyuki S, Carninci P, Prange C, Raha SS, Loquellano NA, Peters GJ, Abramson RD, Mullahy SJ, Bosak SA, McEwan PJ, McKernan KJ, Malek JA, Gunaratne PH, Richards S, Worley KC, Hale S, Garcia AM, Gay LJ, Hulyk SW, Villalon DK, Muzny DM, Sodergren EJ, Lu X, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madan A, Young AC, Shevchenko Y, Bouffard GG, Blakesley RW, Touchman JW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Krzywinski MI, Skalska U, Smailus DE, Schnerch A, Schein JE, Jones SJ, Marra MA, Mammalian Gene Collection Program T (2002) Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci U S A 99(26):16899–16903. https://doi.org/10.1073/pnas.242603899 CrossRefPubMed

12.

Yan F, Ruan XZ, Yang HS, Yao SH, Zhao XY, Gou LT, Ma FX, Yuan Z, Deng HX, Wei YQ (2010) Identification, characterization, and effects of Xenopus laevis PNAS-4 gene on embryonic development. J Biomed Biotechnol 2010:134764–134769. https://doi.org/10.1155/2010/134764 CrossRefPubMedPubMedCentral

13.

Yan F, Gou L, Yang J, Chen L, Tong A, Tang M, Yuan Z, Yao S, Zhang P, Wei Y (2009) A novel pro-apoptosis gene PNAS4 that induces apoptosis in A549 human lung adenocarcinoma cells and inhibits tumor growth in mice. Biochimie 91(4):502–507. https://doi.org/10.1016/j.biochi.2008.12.002 CrossRefPubMed

14.

Yuan Z, Guo W, Yang J, Li L, Wang M, Lei Y, Wan Y, Zhao X, Luo N, Cheng P, Liu X, Nie C, Peng Y, Tong A, Wei Y (2015) PNAS-4, an early DNA damage response gene, induces S phase arrest and apoptosis by activating checkpoint kinases in lung Cancer cells. J Biol Chem 290(24):14927–14944. https://doi.org/10.1074/jbc.M115.658419 CrossRefPubMedPubMedCentral

15.

Li L, Chen DB, Lin C, Cao K, Wan Y, Zhao XY, Nie CL, Yuan Z, Wei YQ (2013) hPNAS-4 inhibits proliferation through S phase arrest and apoptosis: underlying action mechanism in ovarian cancer cells. Apoptosis 18(4):467–479. https://doi.org/10.1007/s10495-012-0797-z CrossRefPubMed

16.

Roy SK, Srivastava RK, Shankar S (2010) Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal 5:10. https://doi.org/10.1186/1750-2187-5-10 CrossRefPubMedPubMedCentral

17.

Yuan Z, Yan F, Wang YS, Liu HY, Gou LT, Zhao XY, Lai ST, Deng HX, Li J, Ding ZY, Xiong SQ, Kan B, Mao YQ, Chen LJ, Wei YQ, Zhao X (2009) PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin. Cancer Chemother Pharmacol 65(1):13–25. https://doi.org/10.1007/s00280-009-0998-5 CrossRefPubMed

18.

Qi X, Song X, Liu P, Yi T, Li S, Xie C, Zheng Y, Bai Y, Sun C, Wei Y, Zhao X (2011) Antitumor effects of PLGA nanoparticles encapsulating the human PNAS-4 gene combined with cisplatin in ovarian cancer. Oncol Rep 26(3):703–710. https://doi.org/10.3892/or.2011.1337 CrossRefPubMed

19.

Hou S, Zhao Z, Yan F, Chen X, Deng H, Chen X, Wang Y, Wei Y (2009) Genetic transfer of PNAS-4 induces apoptosis and enhances sensitivity to gemcitabine in lung cancer. Cell Biol Int 33(3):276–282. https://doi.org/10.1016/j.cellbi.2008.11.014 CrossRefPubMed

20.

Yuan Z, Liu H, Yan F, Wang Y, Gou L, Nie C, Ding Z, Lai S, Zhao Y, Zhao X, Li J, Deng H, Mao Y, Chen L, Wei Y, Zhao X (2009) Improved therapeutic efficacy against murine carcinoma by combining honokiol with gene therapy of PNAS-4, a novel pro-apoptotic gene. Cancer Sci 100(9):1757–1766. https://doi.org/10.1111/j.1349-7006.2009.01242.x CrossRefPubMed

21.

Flanagan L, Meyer M, Fay J, Curry S, Bacon O, Duessmann H, John K, Boland KC, McNamara DA, Kay EW, Bantel H, Schulze-Bergkamen H, Prehn JH (2016) Low levels of Caspase-3 predict favourable response to 5FU-based chemotherapy in advanced colorectal cancer: Caspase-3 inhibition as a therapeutic approach. Cell Death Dis 7:e2087. https://doi.org/10.1038/cddis.2016.7 CrossRefPubMedPubMedCentral

22.

Baharara J, Ramezani T, Divsalar A, Mousavi M, Seyedarabi A (2016) Induction of apoptosis by green synthesized gold nanoparticles through activation of Caspase-3 and 9 in human cervical Cancer cells. Avicenna J Med Biotechnol 8(2):75–83PubMedPubMedCentral

23.

Dolka I, Krol M, Sapierzynski R (2016) Evaluation of apoptosis-associated protein (Bcl-2, Bax, cleaved caspase-3 and p53) expression in canine mammary tumors: an immunohistochemical and prognostic study. Res Vet Sci 105:124–133. https://doi.org/10.1016/j.rvsc.2016.02.004 CrossRefPubMed

24.

Xu Z, Zhang F, Bai C, Yao C, Zhong H, Zou C, Chen X (2017) Sophoridine induces apoptosis and S phase arrest via ROS-dependent JNK and ERK activation in human pancreatic cancer cells. J Exp Clin Cancer Res 36(1):124. https://doi.org/10.1186/s13046-017-0590-5 CrossRefPubMedPubMedCentral

25.

Cheng X, Wang B, Jin Z, Ma D, Yang W, Zhao R, Jing X, Shen B, Peng C, Qiu W (2016) Pseudomonas aeruginosa-mannose-sensitive hemagglutinin inhibits pancreatic cancer cell proliferation and induces apoptosis via the EGFR pathway and caspase signaling. Oncotarget 7(47):77916–77925. https://doi.org/10.18632/oncotarget.12844 CrossRefPubMedPubMedCentral

26.

Chiu TL, Su CC (2017) Tanshinone IIA increases protein expression levels of PERK, ATF6, IRE1alpha, CHOP, caspase3 and caspase12 in pancreatic cancer BxPC3 cellderived xenograft tumors. Mol Med Rep 15(5):3259–3263. https://doi.org/10.3892/mmr.2017.6359 CrossRefPubMed

27.

Castel P, Toska E, Zumsteg ZS, Carmona FJ, Elkabets M, Bosch A, Scaltriti M (2014) Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment. Mol Cell Oncol 1(3):e963447. https://doi.org/10.4161/23723548.2014.963447 CrossRefPubMedPubMedCentral

28.

Wang MC, Jiao M, Wu T, Jing L, Cui J, Guo H, Tian T, Ruan ZP, Wei YC, Jiang LL, Sun HF, Huang LX, Nan KJ, Li CL (2016) Polycomb complex protein BMI-1 promotes invasion and metastasis of pancreatic cancer stem cells by activating PI3K/AKT signaling, an ex vivo, in vitro, and in vivo study. Oncotarget 7(8):9586–9599. https://doi.org/10.18632/oncotarget.7078 CrossRefPubMedPubMedCentral

29.

Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, Kaiser B, Wick MJ, Alvarez C, Cavazos A, Mangold GL, Patnaik A (2012) The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 18(8):2316–2325. https://doi.org/10.1158/1078-0432.CCR-11-2381 CrossRefPubMed

30.

Gao N, Flynn DC, Zhang Z, Zhong XS, Walker V, Liu KJ, Shi X, Jiang BH (2004) G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol 287(2):C281–C291. https://doi.org/10.1152/ajpcell.00422.2003 CrossRefPubMed

31.

Liu CY, Hu MH, Hsu CJ, Huang CT, Wang DS, Tsai WC, Chen YT, Lee CH, Chu PY, Hsu CC, Chen MH, Shiau CW, Tseng LM, Chen KF (2016) Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells. Oncotarget 7(8):9135–9149. https://doi.org/10.18632/oncotarget.7035 CrossRefPubMedPubMedCentral

32.

Chen J, Shao R, Li F, Monteiro M, Liu JP, Xu ZP, Gu W (2015) PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells. Clin Exp Pharmacol Physiol 42(12):1317–1326. https://doi.org/10.1111/1440-1681.12493 CrossRefPubMed

33.

Eser S, Schnieke A, Schneider G, Saur D (2014) Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer 111(5):817–822. https://doi.org/10.1038/bjc.2014.215 CrossRefPubMedPubMedCentral

34.

Cheng HB, Bo Y, Shen WX, Ren XG, Tan JN, Jia ZR, Xu CL (2015) Longikaurin E induces apoptosis of pancreatic cancer cells via modulation of the p38 and PI3K/AKT pathways by ROS. Naunyn Schmiedeberg's Arch Pharmacol 388(6):623–634. https://doi.org/10.1007/s00210-015-1107-4 CrossRef

Title: Desumoylating Isopeptidase 2 (DESI2) Inhibits Proliferation and Promotes Apoptosis of Pancreatic Cancer Cells through Regulating PI3K/AKT/mTOR Signaling Pathway
Authors: Xi Ou
Guang-tao Zhang
Zhe Xu
Jing-sen Chen
Yong Xie
Ji-Kui Liu
Xiao-Ping Liu
Publication date: 01-04-2019
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 2/2019
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-018-0487-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

Promoter Mutation Analysis of ALDOA Gene in Solid Tumors and Acute Leukemias

Combination of MEK Inhibitor and the JAK2-STAT3 Pathway Inhibition for the Therapy of Colon Cancer

Stanniocalcin-2 May Be a Potentially Valuable Prognostic Marker in Endometrial Cancer: a Preliminary Study

Combined Treatment with Autologous CIK Cells, Radiotherapy and Chemotherapy in Advanced Cervical Cancer

Hypermethylated Promoters of Secreted Frizzled-Related Protein Genes are Associated with Colorectal Cancer

JAK Pseudokinase Domain Variants Highlight nRTK VUSs Identified with Next-Generation Sequencing in Solid Tumor Patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer